Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196635 | 1.00 | THRA (0.33) | THRATHRBCA1CA2ESR1 | |
| SCHEMBL505964 | 0.83 | CA1 (0.48) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL505965 | 0.83 | CA1 (0.48) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL1808751 | 0.82 | PLK1 (0.47) | THRATHRBCA2ESR1ESR2 | |
| SCHEMBL1808750 | 0.82 | PLK1 (0.47) | THRATHRBCA2ESR1ESR2 | |
| SCHEMBL11814265 | 0.79 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL2298580 | 0.78 | PRSS1 (0.45) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL2298579 | 0.78 | PRSS1 (0.45) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL18770623 | 0.77 | THRA (0.54) | THRATHRBESR1KDM4E | |
| SCHEMBL18770624 | 0.77 | THRA (0.54) | THRATHRBESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO., INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20060194850-A1 | Novel azole compound | AJINOMOTO CO. INC (JP) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | THRA 1706/4885THRB 2492/4885CA1 2436/4885 |
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | THRA 1706/4885THRB 2492/4885CA1 2436/4885 |
| US-20060194850-A1 | Novel azole compound | LPAR1, LPAR2, LPAR3 | THRA 1706/4885THRB 2492/4885CA1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.